Aca­dia says Nu­plazid cleared main goal in de­pres­sion study, but da­ta ap­pear mixed

In a news-heavy week for de­pres­sion drugs, with of­fer­ings from Alk­er­mes $ALKS and Sage $SAGE un­der FDA scruti­ny, Aca­dia Phar­ma­ceu­ti­cals $ACAD on Wednes­day said “weight­ed av­er­age re­sults” sug­gest pi­ma­vanserin (Nu­plazid) met the main goal in a mid-stage study in­volv­ing pa­tients with ma­jor de­pres­sive dis­or­der (MDD) — but a con­tro­ver­sial two-stage tri­al de­sign in­di­cat­ed the drug failed to im­press in the sec­ond tranche of the tri­al, de­spite the p-val­ue that emerged from the pooled da­ta.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER